Fig. 6: BoNT/A treatment alleviated synapse and spine loss in the reserpine-treated mouse hippocampus. | Acta Pharmacologica Sinica

Fig. 6: BoNT/A treatment alleviated synapse and spine loss in the reserpine-treated mouse hippocampus.

From: Botulinum neurotoxin A ameliorates depressive-like behavior in a reserpine-induced Parkinson’s disease mouse model via suppressing hippocampal microglial engulfment and neuroinflammation

Fig. 6

a, b Representative immunostaining images of excitatory presynaptic marker VGlut2 (red) and postsynaptic marker PSD95 (green) (a) and inhibitory presynaptic marker VGAT (red) and postsynaptic marker Gephyrin (green) (b) in the hippocampal CA1 regions. Scale bar = 5 μm. c, d Quantification of individual and colocalized excitatory pre- and postsynaptic markers (c) and inhibitory pre- and postsynaptic markers (d) (n = 6 images from 3 mice for each group. For VGlut2, F (3, 20) = 7.739, P = 0.0013. For PSD95, F (3, 20) = 7.603, P = 0.0014. For VGlut2 + PSD95, F (3, 20) = 9.593, P = 0.0004. For VGAT, F (3, 20) = 1.191, P = 0.3384. For Gephyrin, F (3, 20) = 0.2680, P = 0.8476. For VGAT + Gephyrin, F (3, 20) = 2.016, P = 0.1440). e Representative images of Golgi-stained dendrite spines of pyramidal neurons in the hippocampal CA1 regions. Scale bar = 5 μm. f Quantification of the dendrite spine density of pyramidal neurons in the hippocampal CA1 regions (n = 12 images from 3 mice for each group. F (3, 44) = 27.26, P < 0.0001). All data are presented as the mean ± SEM. One-way ANOVA with Tukey’s post hoc test was employed. *P  <  0.05, ***P  <  0.001, versus Con group. #P  <  0.05, ##P  <  0.01, ###P  <  0.001, versus the RSP group.

Back to article page